ALPN-101 is a first-in-class dual CD28/ICOS antagonist being developed for the treatment of autoimmune and inflammatory diseases. A Phase 1 healthy volunteer study has been completed and we anticipate the start of ‘BALANCE’, a Phase 1b/2 clinical trial in GVHD, to begin in 2020.
ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor being developed for the treatment of cancer. We anticipate a Phase 1 trial in cancer patients to begin in 2020.
Our Transmembrane Immunomodulatory Protein (TIP) program potentially enhances Engineered Cellular Therapies (ECTs) like CAR-T, TCR, and TIL. TIPs are based upon our core vIgD technology, but are engineered to become part of ECTs to potentially increase specificity, persistence, and/or efficacy.